|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||76.52 - 77.73|
|52 Week Range||71.74 - 80.44|
|Beta (3Y Monthly)||0.44|
|PE Ratio (TTM)||26.92|
|Earnings Date||Oct 31, 2019|
|Forward Dividend & Yield||3.07 (3.99%)|
|1y Target Est||82.62|
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article.
As the Oct. 31 deadline for Britain to leave the European Union approaches, health professionals are warning that shortages of some medicines could worsen in Europe in the event of a no-deal Brexit. Britain's food and drink lobby warned last week that the country would experience shortages of some fresh foods if there is a disorderly no-deal Brexit.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks No biotech stocks hit 52-week highs Monday. Down In The Dumps (Biotech stocks hitting 52-week lows on ...
The Dupixent product developed by French healthcare company Sanofi and its U.S. partner Regeneron has won regulatory approval in Europe for moderate-to-severe cases of eczema in adolescents, the companies said. The European Commission has extended the marketing authorisation for Dupixent in the European Union to include adolescents 12 to 17 years of age with moderate-to-severe atopic dermatitis who are candidates for systemic therapy, Sanofi and Regeneron said in a joint statement on Tuesday.
The Dupixent product developed by French healthcare company Sanofi and its U.S. partner Regeneron has won approval in Europe for adolescents with moderate-to-severe atopic dermatitis, the companies said on Tuesday. The European Commission has extended the marketing authorisation for Dupixent in the European Union to include adolescents 12 to 17 years of age with moderate-to-severe atopic dermatitis who are candidates for systemic therapy, Sanofi and Regeneron said in a joint statement.
August 6, 2019 – A pivotal Phase 3 trial evaluating Dupixent® (dupilumab) to treat severe atopic dermatitis in children aged 6 to 11 years met its primary and secondary endpoints. Dupixent is the first and only biologic to show positive results in this pediatric atopic dermatitis population.
PARIS and TARRYTOWN, NY – August 6, 2019 - The European Commission (EC) today extended the marketing authorization for Dupixent® (dupilumab) in the European Union (EU) to include adolescents 12 to 17 years of age with moderate-to-severe atopic dermatitis who are candidates for systemic therapy. Dupixent is now the first biologic medicine approved in the EU to treat these patients.
Online Availability of Sanofi Group’s Half-Year Financial Report for 2019 PARIS (France) – July 29, 2019 - Sanofi announces that its half-year financial report for the.
Sanofi (NYSE: SNY) shares are trading higher after the company reported better-than-expected second-quarter earnings. The company reported quarterly earnings of $1.47 per share, which beat the analyst consensus estimate of 74 cents. Sanofi reported quarterly sales of $9.663 billion, which beat the analyst consensus estimate of $9.4 billion.
Shares of Lexicon Pharmaceuticals Inc. lost more than half their value (down 53.4%) toward a record low in active premarket trading Monday, after the drug maker said Sanofi wanted to end the alliance around its diabetes treatment Zynquista. The stock was on track to open 38% below its Jan. 29, 2019 record low close of $4.36, with trading volume of 583,000 shares already more than the full-day average of 349,800 shares. Lexicon said it considers Sanofi's notice to be invalid and "in breach of contract." Sanofi's decision to terminate the alliance late Friday came as Lexicon provided preliminary data from a phase 3 trial of Zynquista; Lexicon said it has not yet received the underlying data and expects to conduct its own review and validation of the statistical analysis. Analyst Stephen Wiley at Stifel Nicolaus downgraded Lexicon's stock to hold from buy and cut his price target to $4 from $10, saying Sanofi's notice creates more uncertainty for Lexicon's story, which "already lacked meaningful visibility." The stock has lost 14% year to date through Friday, while the S&P 500 has gained 21%.
PARIS , July 29, 2019 /PRNewswire/ -- Sanofi (NASDAQ: SNY; EURONEXT: SAN) Q2 2019 Change Change at CER H1 2019 Change Change at CER IFRS net sales reported €8,628m +5.5% +3.9% €17,019m +5.9% +4.1% IFRS ...
Sanofi raised its 2019 outlook on the back of second-quarter results lifted by double digit growth at its vaccines and rare diseases businesses. The group is betting on the strong uptake of its drug Dupixent, initially prescribed for atopic dermatitis and later approved for asthma and chronic rhinosinusitis, as it continues marketing and launches of the product. Sanofi booked an 1.8 billion euros impairment charge of intangible assets in the quarter related to haemophilia product Eloctate, after lower sales in the U.S. and a revision of sales projections.
Sanofi SA (NYSE: SNY ) unveils its next round of earnings Monday, July 29. Here is Benzinga's everything-that-matters guide for the earnings announcement. Earnings and Revenue Wall Street analysts see ...